Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa.’ The study aims to assess the disease activity and safety of lutikizumab, an investigational drug, in treating moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition.
The intervention being tested is lutikizumab, administered via subcutaneous injection. The study will compare its efficacy and safety against a placebo in reducing the symptoms of HS.
This interventional study employs a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose of the study is treatment-focused.
The study began on June 27, 2024, with an estimated primary completion date yet to be announced. The last update was submitted on June 30, 2025, indicating ongoing progress.
The outcome of this study could significantly impact AbbVie’s stock performance and investor sentiment, especially if lutikizumab proves effective. With the competitive landscape of dermatological treatments, positive results could position AbbVie favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.